Brett Doliner, MD
See Publications

Texas Heart Institute Positions

Education

  • Medical School:

    University of Miami Leonard M. Miller School of Medicine

  • Residency:

    Massachusetts General Hospital

  • Fellowships:

    The Texas Heart Institute (Cardiovascular Disease)

Honors, Awards and Memberships

  • Chief Cardiology Fellow, 2023-2024

Publications

4862227 3X4Y8D9K 1 alternatives-to-animal-experimentation 10 date desc Doliner 44291 https://www.texasheart.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22MG65EF48%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Doliner%20et%20al.%22%2C%22parsedDate%22%3A%222024%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bstrong%26gt%3BDoliner%26lt%3B%5C%2Fstrong%26gt%3B%2C%20B.%2C%20Gaddar%2C%20H.%2C%20Kalil%2C%20R.%20et%20al.%20%282024%29.%20Modern%20Perspectives%20on%20Hypertrophic%20Cardiomyopathy%26%23x2014%3BNo%20One%20Size%20Fits%20All.%20%26lt%3Bi%26gt%3BTexas%20Heart%20Institute%20Journal%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B51%26lt%3B%5C%2Fi%26gt%3B%2C%20e248423.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.14503%5C%2FTHIJ-24-8423%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.14503%5C%2FTHIJ-24-8423%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Modern%20Perspectives%20on%20Hypertrophic%20Cardiomyopathy%5Cu2014No%20One%20Size%20Fits%20All%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brett%22%2C%22lastName%22%3A%22Doliner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hadeel%22%2C%22lastName%22%3A%22Gaddar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramsey%22%2C%22lastName%22%3A%22Kalil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Postalian%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Despite%20substantial%20advances%20in%20the%20management%20of%20hypertrophic%20cardiomyopathy%2C%20advanced%20heart%20failure%20remains%20a%20major%20cause%20of%20morbidity%20in%20this%20patient%20population.%20This%20narrative%20review%20presents%20the%20case%20of%20a%20patient%20with%20hypertrophic%20obstructive%20cardiomyopathy%20who%20underwent%20alcohol%20septal%20ablation%20to%20frame%20a%20discussion%20of%20modern%20therapies%20for%20hypertrophic%20cardiomyopathy.%20The%20current%20treatment%20landscape%20includes%20medications%2C%20both%20old%20and%20new%2C%20and%20surgical%20and%20procedural%20interventions%20to%20relieve%20mechanical%20obstruction.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Several%20promising%20new%20modalities%20for%20relieving%20obstruction%20are%20in%20the%20nascent%20stages%20of%20development.%22%2C%22date%22%3A%222024%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.14503%5C%2FTHIJ-24-8423%22%2C%22ISSN%22%3A%221526-6702%2C%200730-2347%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fthij.kglmeridian.com%5C%2Fview%5C%2Fjournals%5C%2Fthij%5C%2F51%5C%2F2%5C%2Farticle-e248423.xml%22%2C%22collections%22%3A%5B%223X4Y8D9K%22%5D%2C%22dateModified%22%3A%222025-02-06T23%3A10%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22SIHKI9SX%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Doliner%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bstrong%26gt%3BDoliner%26lt%3B%5C%2Fstrong%26gt%3B%2C%20B.%2C%20Rodriguez%2C%20K.%2C%20Montesi%2C%20S.%20B.%20et%20al.%20%282022%29.%20Interstitial%20lung%20disease%20in%20ANCA-associated%20vasculitis%3A%20associated%20factors%2C%20radiographic%20features%2C%20and%20mortality.%20%26lt%3Bi%26gt%3BRheumatology%20%28Oxford%29%26lt%3B%5C%2Fi%26gt%3B%2C%20keac339.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Frheumatology%5C%2Fkeac339%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Frheumatology%5C%2Fkeac339%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Interstitial%20lung%20disease%20in%20ANCA-associated%20vasculitis%3A%20associated%20factors%2C%20radiographic%20features%2C%20and%20mortality%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brett%22%2C%22lastName%22%3A%22Doliner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%22%2C%22lastName%22%3A%22Rodriguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sydney%20B.%22%2C%22lastName%22%3A%22Montesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaoqing%22%2C%22lastName%22%3A%22Fu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amita%22%2C%22lastName%22%3A%22Sharma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zachary%20S.%22%2C%22lastName%22%3A%22Wallace%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20evaluate%20the%20prevalence%2C%20clinical%20and%20radiographic%20features%2C%20and%20long-term%20outcomes%20of%20interstitial%20lung%20disease%20%28ILD%29%20in%20a%20United%20States-based%20ANCA-associated%20vasculitis%20%28AAV%29%20cohort.%5CnMETHODS%3A%20In%20this%20retrospective%20cohort%20study%2C%20we%20identified%20cases%20of%20ILD%20within%20the%202002-2019%20Mass%20General%20Brigham%20AAV%20Cohort%2C%20a%20consecutive%20inception%20cohort%20of%20PR3-%20or%20MPO-ANCA%2B%20AAV%20patients.%20ILD%20diagnosis%20and%20classification%20as%20fibrotic%20or%20non-fibrotic%20were%20confirmed%20by%20review%20of%20available%20chest%20imaging%20by%20two%20board-certified%20radiologists.%20Cox%20proportional%20hazard%20models%2C%20with%20age%20as%20the%20time%20scale%2C%20were%20used%20to%20estimate%20the%20association%20of%20AAV-ILD%20with%20all-cause%20mortality.%5CnRESULTS%3A%20Of%20684%20patients%20in%20the%20MGB%20AAV%20Cohort%2C%2091%20%2813%25%29%20had%20ILD%20which%20preceded%20the%20diagnosis%20of%20AAV%20by%20a%20mean%20of%202.2%5Cu2009years.%20AAV-ILD%20patients%20were%20older%20%2867%20vs%2060%5Cu2009years%2C%20p%26lt%3B%200.001%29%20than%20patients%20without%20ILD%20but%20the%20distribution%20of%20sex%20and%20race%20was%20similar.%20AAV-ILD%20patients%20were%20more%20often%20MPO-ANCA%5Cu2009%2B%5Cu2009%2893%25%20vs%2065%25%2C%20p%26lt%3B%200.001%29%3B%20among%20MPO-ANCA%2B%20patients%20%28n%5Cu2009%3D%5Cu2009470%29%2C%2085%20%2818%25%29%20had%20ILD.%20The%20majority%20of%20ILD%20was%20fibrotic%20%2876%25%29%20and%20UIP%20was%20the%20most%20common%20ILD%20pattern%20%2842%25%29.%20The%20baseline%20forced%20vital%20capacity%20%28FVC%29%20%25%20predicted%20among%20ILD%20patients%20was%2081%5Cu2009%5Cu00b1%5Cu200920%25.%20Fibrotic%20AAV-ILD%20was%20associated%20with%20a%2058%25%20higher%20risk%20of%20death%20%28aHR%201.58%2C%2095%25%20CI%201.06%2C%202.37%29%20compared%20with%20AAV%20patients%20without%20ILD.%5CnCONCLUSION%3A%20ILD%20is%20a%20frequent%20complication%20of%20AAV%2C%20especially%20MPO-ANCA%2B%20AAV%2C%20often%20preceding%20recognition%20of%20AAV.%20Fibrotic%20AAV-ILD%20is%20associated%20with%20a%20higher%20risk%20of%20death%20than%20AAV%20without%20ILD.%22%2C%22date%22%3A%222022-06-14%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Frheumatology%5C%2Fkeac339%22%2C%22ISSN%22%3A%221462-0332%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22X2D36SJL%22%2C%223X4Y8D9K%22%5D%2C%22dateModified%22%3A%222022-08-10T14%3A30%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22UMASAXTU%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22McDermott%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-13%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMcDermott%2C%20G.%2C%20Fu%2C%20X.%2C%20Cook%2C%20C.%20et%20al.%20%282022%29.%20The%20effect%20of%20achieving%20serological%20remission%20on%20subsequent%20risk%20of%20relapse%2C%20end-stage%20renal%20disease%20and%20mortality%20in%20ANCA-associated%20vasculitis%3A%20a%20target%20trial%20emulation%20study.%20%26lt%3Bi%26gt%3BAnn%20Rheum%20Dis%26lt%3B%5C%2Fi%26gt%3B%2C%20annrheumdis-2022-222439.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fannrheumdis-2022-222439%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fannrheumdis-2022-222439%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20effect%20of%20achieving%20serological%20remission%20on%20subsequent%20risk%20of%20relapse%2C%20end-stage%20renal%20disease%20and%20mortality%20in%20ANCA-associated%20vasculitis%3A%20a%20target%20trial%20emulation%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22McDermott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaoqing%22%2C%22lastName%22%3A%22Fu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Cook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Ahola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brett%22%2C%22lastName%22%3A%22Doliner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Hanberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20H.%22%2C%22lastName%22%3A%22Stone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hyon%20K.%22%2C%22lastName%22%3A%22Choi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuqing%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zachary%20S.%22%2C%22lastName%22%3A%22Wallace%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20evaluate%20the%20effect%20of%20achieving%20a%20negative%20postinduction%20antineutrophil%20cytoplasmic%20antibody%20ANCA%29%20assay%20on%20the%20risk%20of%20relapse%2C%20end-stage%20renal%20disease%20%28ESRD%29%20and%20death%20in%20ANCA-associated%20vasculitis%20%28AAV%29.%5CnMETHODS%3A%20We%20emulated%20a%20target%20trial%20using%20observational%20data%20from%20the%20Mass%20General%20Brigham%20AAV%20cohort%20comparing%20patients%20who%20achieved%20versus%20did%20not%20achieve%20serological%20remission%20%28negative%20ANCA%20assay%29%20within%20180%20days%20of%20induction.%20Outcomes%20were%20relapse%2C%20ESRD%20or%20death%20within%205%20years%2C%20obtained%20from%20medical%20records%2C%20the%20US%20Renal%20Data%20System%20and%20the%20National%20Death%20Index.%20We%20placed%20a%20%26%23039%3Bclone%26%23039%3B%20of%20each%20patient%20in%20both%20trial%20arms%2C%20censored%20those%20deviating%20from%20their%20assigned%20protocol%20and%20weighted%20each%20by%20the%20inverse%20probability%20of%20censoring.%20Outcomes%20were%20assessed%20by%20pooled%20logistic%20regression.%5CnRESULTS%3A%20The%20study%20included%20506%20patients%20with%20AAV.%20The%20mean%20age%20was%2061%20years%20%28SD%2018%29%20and%20the%20majority%20were%20women%20%2858%25%29%2C%20white%20%2887%25%29%2C%20myeloperoxidase-ANCA%2B%20%2872%25%29%20and%20had%20renal%20involvement%20%2868%25%29.%20Rituximab%20%2859%25%29%20or%20cyclophosphamide%20%2833%25%29%20was%20most%20often%20used%20for%20induction%20treatment.%20Within%205%20years%2C%2081%20%2816%25%29%20died%2C%2051%20%2810%25%29%20had%20ESRD%20and%2064%20%2813%25%29%20had%20relapse.%20Patients%20treated%20to%20a%20negative%20ANCA%20assay%20within%20180%20days%20had%20HR%200.55%20%2895%25%20CI%200.38%20to%200.81%29%20for%20relapse%20and%20HR%200.87%20%2895%25%20CI%200.61%20to%201.25%29%20for%20the%20composite%20of%20ESRD%20or%20death%20within%205%20years.%5CnCONCLUSIONS%3A%20In%20this%20emulated%20target%20trial%20from%20a%20large%20AAV%20cohort%2C%20achieving%20serological%20remission%20within%20180%20days%20of%20induction%20was%20associated%20with%20lower%20risk%20of%20relapse%2C%20but%20no%20statistically%20significant%20difference%20in%20ESRD%20or%20mortality%20outcomes.%22%2C%22date%22%3A%222022-06-13%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fannrheumdis-2022-222439%22%2C%22ISSN%22%3A%221468-2060%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22X2D36SJL%22%2C%223X4Y8D9K%22%5D%2C%22dateModified%22%3A%222022-08-10T14%3A30%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22VXSAVWA6%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dueker%20et%20al.%22%2C%22parsedDate%22%3A%222020-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDueker%2C%20N.%20D.%2C%20%26lt%3Bstrong%26gt%3BDoliner%26lt%3B%5C%2Fstrong%26gt%3B%2C%20B.%2C%20Gardener%2C%20H.%20et%20al.%20%282020%29.%20Extreme%20Phenotype%20Approach%20Suggests%20Taste%20Transduction%20Pathway%20for%20Carotid%20Plaque%20in%20a%20Multi-Ethnic%20Cohort.%20%26lt%3Bi%26gt%3BStroke%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B51%26lt%3B%5C%2Fi%26gt%3B%2C%202761%26%23x2013%3B2769.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FSTROKEAHA.120.028979%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FSTROKEAHA.120.028979%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Extreme%20Phenotype%20Approach%20Suggests%20Taste%20Transduction%20Pathway%20for%20Carotid%20Plaque%20in%20a%20Multi-Ethnic%20Cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%20D.%22%2C%22lastName%22%3A%22Dueker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brett%22%2C%22lastName%22%3A%22Doliner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hannah%22%2C%22lastName%22%3A%22Gardener%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chuanhui%22%2C%22lastName%22%3A%22Dong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ashley%22%2C%22lastName%22%3A%22Beecham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Della-Morte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralph%20L.%22%2C%22lastName%22%3A%22Sacco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susan%20H.%22%2C%22lastName%22%3A%22Blanton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liyong%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tatjana%22%2C%22lastName%22%3A%22Rundek%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20PURPOSE%3A%20Carotid%20plaque%20is%20a%20heritable%20trait%20and%20a%20strong%20predictor%20of%20vascular%20events.%20Several%20loci%20have%20been%20identified%20for%20carotid%20plaque%2C%20however%2C%20studies%20in%20minority%20populations%20are%20lacking.%20Within%20a%20multi-ethnic%20cohort%2C%20we%20have%20identified%20individuals%20with%20extreme%20total%20carotid%20plaque%20area%20%28TCPA%29%2C%20that%20is%2C%20higher%20or%20lower%20TCPA%20than%20expected%20based%20on%20traditional%20vascular%20risk%20factors%20%28age%2C%20sex%2C%20smoking%2C%20diabetes%20mellitus%2C%20hypertension%2C%20etc%29.%20We%20hypothesized%20that%20these%20individuals%20are%20enriched%20with%20genetic%20variants%20accounting%20for%20the%20plaque%20burden%20that%20cannot%20be%20explained%20by%20traditional%20vascular%20risk%20factors.%20Herein%2C%20we%20sought%20to%20identify%20the%20genetic%20basis%20for%20TCPA%20using%20the%20multi-ethnic%20cohort.%5CnMETHODS%3A%20Three%20hundred%20forty%20participants%20%28170%20from%20each%20extreme%20group%29%20from%203%20race%5C%2Fethnic%20groups%20%2853%25%20Hispanic%2C%2029%25%20non-Hispanic%20Black%2C%20and%2018%25%20non-Hispanic%20White%29%20were%20genotyped%20using%20a%20genome-wide%20single-nucleotide%20polymorphism%20%28SNP%29%20array%20and%20imputed%20using%201000Genome%20data.%20SNP-based%20analyses%20using%20logistic%20regression%20and%20gene-based%20analyses%20using%20VEGAS2%20were%20performed%20within%20each%20race%5C%2Fethnic%20group%20and%20then%20meta-analyzed.%20Genes%20with%20P%26lt%3B0.001%20were%20included%20in%20an%20overrepresentation%20enrichment%20pathway%20analysis%20using%20WebGestalt.%20Promising%20findings%20were%20tested%20for%20association%20with%20ischemic%20stroke%20using%20the%20MEGASTROKE%20Consortium%20data%20set.%5CnRESULTS%3A%20No%20SNP%20or%20gene%20reached%20genome-wide%20significance.%20In%20the%20pathway%20analysis%2C%20GO%3A0050913%20%28sensory%20perception%20of%20bitter%20taste%29%20gene%20set%20was%20significantly%20enriched%20%28P%3D4.5%5Cu00d710-6%2C%20false%20discovery%20rate%3D0.04%29%2C%20which%20was%20confirmed%20in%20MEGASTROKE%20%28P%3D0.01%29.%20Within%20the%20GO%3A0050913%20gene%20set%2C%203%20genes%20were%20associated%20with%20extreme%20TCPA%20in%20our%20study%20%28P%26lt%3B0.001%29%3A%20TAS2R20%2C%20TAS2R50%2C%20and%20ITPR3.%20In%20TAS2R50%2C%20rs1376251%20is%20the%20top%20SNP%20and%20has%20been%20associated%20with%20myocardial%20infarction%20by%20others.%20In%20ITPR3%2C%20a%20SNP%20with%20high%20regulatory%20potential%20%28rs3818527%2C%20RegulomeScore%3D1f%29%2C%20and%20ITPR3%20itself%20were%20among%20the%20top%20SNP-based%20and%20gene-based%20results%20and%20showed%20consistent%20evidence%20for%20association%20in%20all%20ethnic%20groups%20%28P%26lt%3B0.05%29.%5CnCONCLUSIONS%3A%20Extreme%20TCPA%20analysis%20identified%20new%20candidate%20genes%20for%20carotid%20plaque%20in%20understudied%20populations.%22%2C%22date%22%3A%222020-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1161%5C%2FSTROKEAHA.120.028979%22%2C%22ISSN%22%3A%221524-4628%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%223X4Y8D9K%22%5D%2C%22dateModified%22%3A%222022-08-10T14%3A30%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22KUHYYJNT%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Doliner%20et%20al.%22%2C%22parsedDate%22%3A%222019-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bstrong%26gt%3BDoliner%26lt%3B%5C%2Fstrong%26gt%3B%2C%20B.%2C%20Jaller%2C%20J.%20A.%2C%20Lopez%2C%20A.%20J.%20et%20al.%20%282019%29.%20Treatments%20to%20prevent%20primary%20venous%20ulceration%20after%20deep%20venous%20thrombosis.%20%26lt%3Bi%26gt%3BJ%20Vasc%20Surg%20Venous%20Lymphat%20Disord%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B7%26lt%3B%5C%2Fi%26gt%3B%2C%20260-271.e1.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jvsv.2018.12.009%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jvsv.2018.12.009%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Treatments%20to%20prevent%20primary%20venous%20ulceration%20after%20deep%20venous%20thrombosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brett%22%2C%22lastName%22%3A%22Doliner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20A.%22%2C%22lastName%22%3A%22Jaller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alberto%20J.%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hadar%22%2C%22lastName%22%3A%22Lev-Tov%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20This%20systematic%20review%20and%20meta-analysis%20aimed%20to%20assess%20whether%20compression%20stockings%20or%20other%20interventions%20reduce%20the%20incidence%20of%20venous%20ulceration%20after%20acute%20deep%20venous%20thrombosis.%5CnMETHODS%3A%20We%20searched%20PubMed%20and%20Embase%20for%20randomized%20controlled%20trials%20%28RCTs%29%2C%20restricted%20to%20English%2C%20Spanish%2C%20and%20Hebrew%2C%20related%20to%20post-thrombotic%20syndrome%20and%20venous%20ulceration%20in%20participants%20with%20confirmed%20deep%20venous%20thrombosis.%20Our%20primary%20statistical%20assessment%20was%20the%20Peto%20odds%20ratio%20%28OR%29.%5CnRESULTS%3A%20Our%20search%20generated%2023%20RCTs%20meeting%20inclusion%20and%20exclusion%20criteria%2C%20summing%206162%20patients%20and%20146%20ulcerative%20events.%20Trials%20were%20categorized%20into%20compression%2C%20low-molecular-weight%20heparin%20%28LMWH%29%2C%20procedural%20thrombolysis%2C%20medical%20thrombolysis%2C%20or%20miscellaneous.%20Six%20compression%20trials%20were%20identified%2C%20of%20which%20five%20were%20included%20in%20meta-analysis.%20Compression%20compared%20with%20placebo%20did%20not%20reduce%20venous%20ulceration%20%28OR%2C%200.915%3B%2095%25%20confidence%20interval%20%5BCI%5D%2C%200.475-1.765%29%2C%20and%20long-term%20compression%20was%20not%20superior%20to%20short-term%20compression%20%28OR%2C%201.36%3B%2095%25%20CI%2C%200.014-1.31%29.%20Four%20LMWH%20trials%20were%20identified%20but%20were%20not%20subjected%20to%20meta-analysis%20because%20of%20intertrial%20heterogeneity.%20One%20trial%2C%20comparing%20extended%20tinzaparin%20with%20warfarin%2C%20demonstrated%20eight%20ulcers%20in%20the%20warfarin%20group%20and%20one%20ulcer%20in%20the%20LMWH%20group%20%28relative%20risk%2C%200.125%3B%20P%5Cu00a0%26lt%3B%20.05%29.%20Three%20procedural%20thrombolysis%20trials%20were%20pooled%20into%20meta-analysis%3B%20fewer%20ulcerative%20events%20occurred%20in%20procedural%20thrombolysis%20patients%2C%20but%20the%20effect%20was%20not%20significant%20%28OR%2C%200.677%3B%2095%25%20CI%2C%200.338-1.358%29.%20Eight%20medical%20thrombolysis%20trials%20were%20identified.%20Pooled%20analysis%20of%20five%20trials%20demonstrated%20a%20protective%20effect%20on%20ulceration%20in%20streptokinase%20patients%20vs%20standard%20heparinization%20%28OR%2C%200.125%3B%2095%25%20CI%2C%200.021-0.739%29.%20However%2C%20these%20trials%20were%20of%20poor-quality%20study%20design%2C%20had%20small%20sample%20size%2C%20and%20had%20poor%20overall%20outcomes.%20Miscellaneous%20studies%20included%20a%20trial%20of%20hidrosmina%2C%20a%20vasoactive%20flavonoid%2C%20and%20a%20trial%20comparing%206-month%20warfarin%20treatment%20with%206%5Cu00a0weeks%3B%20neither%20trial%20had%20significant%20outcomes.%20Intertrial%20heterogeneity%20was%20not%20adequately%20assessed%20with%20the%20I2%20value%20as%20venous%20ulceration%20is%20a%20rare%20event%3B%20the%20Grading%20of%20Recommendations%20Assessment%2C%20Development%2C%20and%20Evaluation%20evidence%20for%20most%20trials%20was%20very%20low%2C%20with%20the%20exception%20of%20procedural%20thrombolysis%20trials%2C%20for%20which%20it%20was%20low.%5CnCONCLUSIONS%3A%20We%20found%20insufficient%20evidence%20to%20assess%20whether%20compression%20or%20other%20interventions%20protect%20against%20venous%20ulceration.%20To%20develop%20guidelines%20for%20treatment%20decisions%20related%20to%20prevention%20of%20venous%20ulceration%2C%20high-powered%20RCTs%20investigating%20venous%20leg%20ulcers%20as%20a%20primary%20outcome%20are%20required.%22%2C%22date%22%3A%222019-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jvsv.2018.12.009%22%2C%22ISSN%22%3A%222213-3348%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%223X4Y8D9K%22%5D%2C%22dateModified%22%3A%222022-08-10T14%3A30%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22XIAMA8K2%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Darwin%20et%20al.%22%2C%22parsedDate%22%3A%222018-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDarwin%2C%20E.%2C%20Hirt%2C%20P.%20A.%2C%20Fertig%2C%20R.%20et%20al.%20%282018%29.%20Alopecia%20Areata%3A%20Review%20of%20Epidemiology%2C%20Clinical%20Features%2C%20Pathogenesis%2C%20and%20New%20Treatment%20Options.%20%26lt%3Bi%26gt%3BInt%20J%20Trichology%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B10%26lt%3B%5C%2Fi%26gt%3B%2C%2051%26%23x2013%3B60.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.4103%5C%2Fijt.ijt_99_17%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.4103%5C%2Fijt.ijt_99_17%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Alopecia%20Areata%3A%20Review%20of%20Epidemiology%2C%20Clinical%20Features%2C%20Pathogenesis%2C%20and%20New%20Treatment%20Options%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Evan%22%2C%22lastName%22%3A%22Darwin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Penelope%20A.%22%2C%22lastName%22%3A%22Hirt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raymond%22%2C%22lastName%22%3A%22Fertig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brett%22%2C%22lastName%22%3A%22Doliner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gina%22%2C%22lastName%22%3A%22Delcanto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joaquin%20J.%22%2C%22lastName%22%3A%22Jimenez%22%7D%5D%2C%22abstractNote%22%3A%22Alopecia%20areata%20%28AA%29%20is%20a%20complex%20autoimmune%20condition%20that%20causes%20nonscarring%20hair%20loss.%20It%20typically%20presents%20with%20sharply%20demarcated%20round%20patches%20of%20hair%20loss%20and%20may%20present%20at%20any%20age.%20In%20this%20article%2C%20we%20review%20the%20epidemiology%2C%20clinical%20features%2C%20pathogenesis%2C%20and%20new%20treatment%20options%20of%20AA%2C%20with%20a%20focus%20on%20the%20immunologic%20mechanism%20underlying%20the%20treatment.%20While%20traditional%20treatment%20options%20such%20as%20corticosteroids%20are%20moderately%20effective%2C%20a%20better%20understanding%20of%20the%20disease%20pathogenesis%20may%20lead%20to%20the%20development%20of%20new%20treatments%20that%20are%20more%20directed%20and%20effective%20against%20AA.%20Sources%20were%20gathered%20from%20PubMed%2C%20Embase%2C%20and%20the%20Cochrane%20database%20using%20the%20keywords%3A%20alopecia%2C%20alopecia%20areata%2C%20hair%20loss%2C%20trichoscopy%2C%20treatments%2C%20pathogenesis%2C%20and%20epidemiology.%22%2C%22date%22%3A%222018%20Mar-Apr%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.4103%5C%2Fijt.ijt_99_17%22%2C%22ISSN%22%3A%220974-7753%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%223X4Y8D9K%22%5D%2C%22dateModified%22%3A%222022-08-10T14%3A30%3A43Z%22%7D%7D%2C%7B%22key%22%3A%2243UUKCK6%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Doliner%20et%20al.%22%2C%22parsedDate%22%3A%222018-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bstrong%26gt%3BDoliner%26lt%3B%5C%2Fstrong%26gt%3B%2C%20B.%2C%20Dong%2C%20C.%2C%20Blanton%2C%20S.%20H.%20et%20al.%20%282018%29.%20Apolipoprotein%20E%20Gene%20Polymorphism%20and%20Subclinical%20Carotid%20Atherosclerosis%3A%20The%20Northern%20Manhattan%20Study.%20%26lt%3Bi%26gt%3BJ%20Stroke%20Cerebrovasc%20Dis%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B27%26lt%3B%5C%2Fi%26gt%3B%2C%20645%26%23x2013%3B652.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jstrokecerebrovasdis.2017.09.053%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jstrokecerebrovasdis.2017.09.053%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Apolipoprotein%20E%20Gene%20Polymorphism%20and%20Subclinical%20Carotid%20Atherosclerosis%3A%20The%20Northern%20Manhattan%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brett%22%2C%22lastName%22%3A%22Doliner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chuanhui%22%2C%22lastName%22%3A%22Dong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susan%20H.%22%2C%22lastName%22%3A%22Blanton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hannah%22%2C%22lastName%22%3A%22Gardener%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mitchell%20S.%20V.%22%2C%22lastName%22%3A%22Elkind%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralph%20L.%22%2C%22lastName%22%3A%22Sacco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ryan%20T.%22%2C%22lastName%22%3A%22Demmer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Moise%22%2C%22lastName%22%3A%22Desvarieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tatjana%22%2C%22lastName%22%3A%22Rundek%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Apolipoprotein%20E%20%28APOE%29%20polymorphism%20has%20previously%20been%20associated%20with%20carotid%20intima-media%20thickness%20%28cIMT%29%20in%20predominantly%20Caucasian%20populations.%20We%20sought%20to%20test%20the%20strength%20of%20the%20relationship%20between%20APOE-%5Cu03b54%20carrier%20status%20and%20subclinical%20atherosclerosis%20in%20a%20tri-ethnic%20population%20with%20a%20large%20Hispanic%20representation.%5CnMETHODS%3A%20We%20assessed%20the%20association%20between%20APOE%20polymorphism%20and%20cIMT%20and%20plaque%20burden%20among%201243%20stroke-free%20individuals%20%28mean%20age%2069%20years%2C%2065%25%20Hispanic%2C%2018%25%20black%2C%2017%25%20white%29%20using%20a%20sequence%20of%20multivariable%20regression%20models.%5CnRESULTS%3A%20After%20adjusting%20for%20demographics%2C%20vascular%20risk%20factors%20and%20plasma%20low-density%20lipoprotein%20%28LDL%29%20levels%2C%20APOE-%5Cu03b54%20carrier%20status%20was%20positively%20associated%20with%20cIMT%20%28mean%20difference%2C%20.013%5Cu2009mm%3B%2095%25%20confidence%20interval%2C%20.003-.023%5Cu2009mm%29.%20The%20APOE-%5Cu03b54%20association%20with%20cIMT%20appeared%20to%20be%20segment-specific%20with%20greater%20differences%20in%20IMT%20between%20APOE-%5Cu03b54%20carriers%20and%20noncarriers%20in%20the%20common%20carotid%20artery%20%28CCA%2C%20.014%5Cu2009mm%29%20and%20bifurcation%20%28.017%5Cu2009mm%29%20than%20in%20the%20internal%20carotid%20artery%20%28ICA%29%20IMT%20%28.007%5Cu2009mm%29.%20This%20relationship%20was%20not%20modified%20by%20race-ethnicity.%20Presence%20of%20diabetes%20modified%20the%20%5Cu03b54-cIMT%20relationship%20in%20CCA%20%28P%5Cu2009%3D%5Cu2009.045%29%20and%20ICA%20%28P%5Cu2009%3D%5Cu2009.046%29.%20APOE-%5Cu03b54%20carrier%20status%20was%20not%20associated%20with%20plaque%20presence%20or%20plaque%20area.%5CnCONCLUSIONS%3A%20APOE-%5Cu03b54%20carriers%20had%20elevated%20cIMT%20independent%20of%20demographics%20and%20vascular%20risk%20factors%20including%20LDL%20levels.%20Diabetes%20was%20an%20effect%20modifier%20of%20the%20relationship%20between%20APOE-%5Cu03b54%20and%20IMT%2C%20such%20that%20%5Cu03b54%20carriers%20with%20diabetes%20had%20greater%20IMT%20in%20the%20CCA%20and%20ICA%20than%20those%20without%20diabetes.%20The%20APOE-IMT%20relationship%20was%20not%20modified%20by%20race-ethnicity.%22%2C%22date%22%3A%222018-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jstrokecerebrovasdis.2017.09.053%22%2C%22ISSN%22%3A%221532-8511%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%223X4Y8D9K%22%5D%2C%22dateModified%22%3A%222022-08-10T14%3A30%3A43Z%22%7D%7D%5D%7D
Doliner, B., Gaddar, H., Kalil, R. et al. (2024). Modern Perspectives on Hypertrophic Cardiomyopathy—No One Size Fits All. Texas Heart Institute Journal 51, e248423. https://doi.org/10.14503/THIJ-24-8423.
Doliner, B., Rodriguez, K., Montesi, S. B. et al. (2022). Interstitial lung disease in ANCA-associated vasculitis: associated factors, radiographic features, and mortality. Rheumatology (Oxford), keac339. https://doi.org/10.1093/rheumatology/keac339.
McDermott, G., Fu, X., Cook, C. et al. (2022). The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study. Ann Rheum Dis, annrheumdis-2022-222439. https://doi.org/10.1136/annrheumdis-2022-222439.
Dueker, N. D., Doliner, B., Gardener, H. et al. (2020). Extreme Phenotype Approach Suggests Taste Transduction Pathway for Carotid Plaque in a Multi-Ethnic Cohort. Stroke 51, 2761–2769. https://doi.org/10.1161/STROKEAHA.120.028979.
Doliner, B., Jaller, J. A., Lopez, A. J. et al. (2019). Treatments to prevent primary venous ulceration after deep venous thrombosis. J Vasc Surg Venous Lymphat Disord 7, 260-271.e1. https://doi.org/10.1016/j.jvsv.2018.12.009.
Darwin, E., Hirt, P. A., Fertig, R. et al. (2018). Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options. Int J Trichology 10, 51–60. https://doi.org/10.4103/ijt.ijt_99_17.
Doliner, B., Dong, C., Blanton, S. H. et al. (2018). Apolipoprotein E Gene Polymorphism and Subclinical Carotid Atherosclerosis: The Northern Manhattan Study. J Stroke Cerebrovasc Dis 27, 645–652. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.09.053.